Travere Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $25 price target.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics shares rose following an upgrade from Guggenheim, which changed its rating from Neutral to Buy and set a $25 price target.
September 09, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics received an upgrade from Guggenheim, moving from Neutral to Buy, with a new price target of $25. This positive analyst action has led to an increase in the stock's trading price.
The upgrade from Guggenheim is a significant positive signal for investors, likely increasing demand for the stock and driving up its price. The new price target of $25 suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100